Back to top
more

UnitedHealth Group (UNH)

(Real Time Quote from BATS)

$569.10 USD

569.10
2,394,355

+3.07 (0.54%)

Updated Oct 18, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 7% (233 out of 250)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) due to its strong fiscal fourth-quarter results.

LabCorp (LH) Debuts At-home Collection Kit for Diabetes Testing

by Zacks Equity Research

LabCorp's (LH) at-home collection kit makes it effortless for consumers to understand their diabetes risk and health status using an innovative and approved collection device.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Strong performance across the Diabetes Care and EPD businesses is driving the top line for Abbott (ABT).

UnitedHealth (UNH) Unit Chosen to Aid Missouri Medicaid Members

by Zacks Equity Research

UnitedHealth Group's (UNH) unit, UnitedHealthcare, has been selected by Missouri and entrusted to administer the MO HealthNet Managed Care Program to serve the state's Medicaid beneficiaries.

QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer

by Zacks Equity Research

The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.

Medtronic's (MDT) Onyx Frontier DES Receives FDA Approval

by Zacks Equity Research

Medtronic's (MDT) Onyx Frontier DES is utilized to treat patients with CAD.

    Here's Why You Should Retain Charles River (CRL) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.

      Here's Why Investors Should Retain Medtronic (MDT) Stock

      by Zacks Equity Research

      Investors are optimistic about Medtronic's (MDT) rising market share gains and ongoing business recovery.

      Here's Why You Should Retain LabCorp (LH) Stock for Now

      by Zacks Equity Research

      Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.

      NEOGEN (NEOG) Introduces InfiniSEEK for Cattle Breeders

      by Zacks Equity Research

      NEOGEN's (NEOG) recent launch enables simultaneous low-pass whole genome sequencing and high-coverage genotyping at regions of interest.

        Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Grow

        by Zacks Equity Research

        Alcon (ALC) delivers better-than-expected results in the first quarter, with strong performance across both franchises driving the top line.

        STERIS (STE) Q4 Earnings Surpass Estimates, Gross Margin Rises

        by Zacks Equity Research

        Robust performances across all four reporting segments drive STERIS' (STE) fiscal fourth-quarter revenues.

        Globus Medical (GMED) Q1 Earnings Miss Estimates, Margins Dip

        by Zacks Equity Research

        According to Globus Medical (GMED), its Q1 results reflect modest revenue growth against a difficult prior-year comparison, coupled with COVID-related revenue impacts in key countries.

        Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up

        by Zacks Equity Research

        Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.

        Here's Why You Should Hold on to Henry Schein (HSIC) Now

        by Zacks Equity Research

        Investors are optimistic about Henry Schein (HSIC) on favorable international Dental business trends and bullish guidance.

          Here's Why You Should Hold on to CVS Health (CVS) For Now

          by Zacks Equity Research

          Investors are optimistic about CVS Health's (CVS) better-than-expected results and strong retail sales.

          National Vision (EYE) Tops Q1 Earnings Estimates, Cuts '22 View

          by Zacks Equity Research

          National Vision (EYE) reports better-than-expected earnings and an increase in store count for the first quarter.

          Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays

          by Zacks Equity Research

          Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.

          Shockwave Medical (SWAV) Beats on Q1 Earnings & Revenues

          by Zacks Equity Research

          Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and expansion in gross margin.

          Mednax (MD) Down 20% Despite Q1 Earnings Beat on Patient Volumes

          by Zacks Equity Research

          Mednax (MD) continues to anticipate revenues of $2 billion and adjusted EBITDA of at least $270 million for 2022.

          Allscripts' (MDRX) Stock Falls 8.8% Post Q1 Earnings Miss

          by Zacks Equity Research

          Allscripts' (MDRX) robust Q1 results demonstrate strength in both segments.

            Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates

            by Zacks Equity Research

            Intersect ENT (XENT) records lower-than-expected revenues for the first quarter, with mounting operating costs impacting the bottom line.

              Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat

              by Zacks Equity Research

              Glaukos' (GKOS) soft Q1 results fail to impress investors.

              SmileDirectClub (SDC) Q1 Earnings Lag Estimates, Margins Fall

              by Zacks Equity Research

              SmileDirectClub's (SDC) revenues declined year over year in the first quarter due to a drop in unique aligner shipments.

                Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays

                by Zacks Equity Research

                Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.